HA35 Moderate Alcoholic Hepatitis (AH) Study

NCT ID: NCT05018481

Last Updated: 2025-11-17

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2027-10-01

Brief Summary

Eligible participants will be asked to take a placebo/treatment capsule for 90 days and participate in two in-person study visits, one at the start of the 90 days and the second at the completion of study supplement administration. Both visits will include a physical exam, clinical labs, body composition measurements, muscle strength tests, questionnaires, and urine and stool collections. Additionally, a sugar cocktail will be consumed to measure gut permeability and a muscle biopsy will be collected. The day after the visits, you will need to return to drop off the 24-hour urine collection.

Two phone visits will be performed in between the in-person visits at day 30 and 60 where you will be asked a series of questionnaires as well as asked about study supplement compliance.

Detailed Description

Written informed consent will be obtained during the baseline visit (day 1). Patients will given a physical exam and a blood test will be obtained if not in their medical chart. The subjects who meet the criteria after the screening visit will have the following procedures: A. Body composition will be quantified by whole-body dual energy X-ray absorptiometry (DEXA), Bioelectric Impedance Analysis (BIA), chair stands, 3 position balance and hand grip strength by dynamometry. B. Muscle biopsy from the lateral portion of vastus lateralis, about 20 cm above knee, C. Questionnaires, D. Blood collection, E. Collection of stool samples, F. Sugar cocktail administration, and G. Urine collection (24 hour)

After baseline measures have been completed, patients will be randomized in a 1:1 ratio to either standard of care (SOC) + HA35 or SOC + placebo (140 mg/d) for a total of 3 months post enrollment.

The subjects will be recalled after 3 months. The visit and the procedures conducted on day 90 will be similar to the baseline study visit.

Conditions

Alcoholic Hepatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: TRIPLE

Study Groups

HA35 Placebo Group

24 study participants will receive the standard of care treatment for AH and a 90-day supply of a placebo to take once a day with breakfast.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

A placebo will be given in capsule form to study participants

HA35 Treatment Group

24 study participants will receive the standard of care treatment for AH and a 90-day supply of a HA35 to take once a day with breakfast.

Group Type: ACTIVE_COMPARATOR

Sodium Hyaluronate

Intervention Type: DRUG

Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants

Interventions

Sodium Hyaluronate

Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants

Intervention Type: DRUG

Placebo

A placebo will be given in capsule form to study participants

Intervention Type: DRUG

Other Intervention Names

HA35

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of alcoholic hepatitis defined as:

• Regular consumption of alcohol with an intake of >60 g daily or >420 g weekly on average for men and >40 g daily or >280 g weekly on average for women for 6 months or more

AND

• MELD <21
• Serum total bilirubin >3 mg/dL
• AST >50 IU/I; AST:ALT ratio >1.5; Both AST and ALT <400 IU/I

OR Histologic evidence of AH.

Exclusion Criteria

• Pregnant or breastfeeding women
• Patients with gastrointestinal bleeding within 2 weeks
• Active infection (positive blood or ascitic fluid culture)
• Overt encephalopathy
• Renal failure and/or on dialysis
• Medications that alter muscle protein metabolism
• Myopathies
• Other end-stage organ diseases
• Malignancy
• Solid organ or hematopoietic transplantation
• Active alcohol withdrawal or ongoing participation in a Clinical Institute Withdrawal Assessment (CIWA) protocol
• History of recent upper gastrointestinal resection within past 6 months
• Acute or chronic liver disease due to other active causes, in addition to alcoholic liver disease
• Inability to provide consent
• Creatinine >2mg/dL
• Platelets <60,000k/ul
• PT/INR >1.7
• Presence of pedal edema
• Use of anti-platelet/anticoagulation drugs or medications that interfere with blood clotting

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Cleveland Clinic

OTHER

Sponsor Role: lead

Responsible Party

Srinivasan Dasarathy

Staff Physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Cleveland Clinic

Cleveland, Ohio, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Srinivasan Dasarathy, MD

Role: CONTACT

dasaras@ccf.org

216-318-7010

Annette Bellar

Role: CONTACT

bellara@ccf.org

Facility Contacts

Annette Bellar

Role: primary

Other Identifiers

21-605

Identifier Type: -

Identifier Source: org_study_id